(UroToday.com) Advances in imaging have dramatically reshaped prostate cancer diagnosis, staging, and treatment. While multiparametric MRI (mpMRI) of the prostate has dramatically changed prostate cancer diagnosis, molecularly-targeted imaging has reshaped disease staging and detection of recurrent disease. Conventional imaging approaches using including computed tomography (CT) and bone scan have relatively limited sensitivity to detect disease recurrence following initial local therapy. A number of studies have demonstrated that prostate-specific membrane antigen (PSMA) targeting PET radiopharmaceuticals detect disease not identified based on conventional imaging, with greater accuracy, for initial staging and detection of biochemical recurrence. In a presentation in the Center for Therapy Excellence Young Investigator Award session at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2021 Annual Meeting, Dr. Petra Lovrec discussed the potential for prostate-specific membrane antigen (PSMA)-based 18F-DCFPyL (PyL) PET imaging to predict metastatic disease response to therapy and to assess metastatic disease patterns of response and recurrence for patients receiving neoadjuvant chemohormonal therapy followed by prostatectomy for high-risk prostate cancer.